Equities Analysts Offer Predictions for Context Therapeutics Inc.’s Q3 2024 Earnings (NASDAQ:CNTX)

Context Therapeutics Inc. (NASDAQ:CNTX) – Investment analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for Context Therapeutics in a research note issued to investors on Monday, September 23rd. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.16) per share for the quarter, down from their previous forecast of ($0.03). HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.52) EPS, FY2025 earnings at ($0.36) EPS, FY2026 earnings at ($0.50) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.70) EPS.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04.

Context Therapeutics Stock Up 0.5 %

NASDAQ CNTX opened at $1.86 on Thursday. The company has a 50-day simple moving average of $2.30 and a two-hundred day simple moving average of $1.90. Context Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.75. The firm has a market cap of $139.50 million, a price-to-earnings ratio of -1.40 and a beta of 2.31.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently bought and sold shares of CNTX. Renaissance Technologies LLC grew its holdings in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares during the last quarter. Opaleye Management Inc. purchased a new stake in shares of Context Therapeutics during the fourth quarter worth about $1,102,000. Affinity Asset Advisors LLC grew its stake in shares of Context Therapeutics by 392.4% in the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Ally Bridge Group NY LLC increased its holdings in Context Therapeutics by 159.8% during the 2nd quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock valued at $3,782,000 after purchasing an additional 1,160,281 shares during the period. Finally, Nantahala Capital Management LLC bought a new position in Context Therapeutics during the 2nd quarter valued at approximately $3,881,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.